This trial has been terminated.

Condition age-related macular degeneration
Treatment fovista® (anti-pdgf bb) plus anti-vegf
Phase phase 2
Targets VEGF, PDGF
Sponsor Ophthotech Corporation
Start date July 2014
End date May 2017
Trial size 101 participants
Trial identifier NCT02214628, OPH1005


The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a "Pre-Treatment" or as a "Simultaneous" regimen followed by quarterly administration.
fovista® (anti-pdgf bb) plus anti-vegf

Primary Outcomes

time frame: 2 years

Eligibility Criteria

All participants at least 50 years old.

Inclusion Criteria: - Subjects of either gender aged ≥ 50 years - All flourescein angiographic subtypes with presence of active choroidal neovascularization Exclusion Criteria: - Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication - Subjects with subfoveal scar or subfoveal atrophy - Any ocular or periocular infection in the past twelve (12) weeks - History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant

Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Ophthotech Corporation.